Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Increases By 22.8%

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 586,355 shares, a growth of 22.8% from the November 30th total of 477,324 shares. Based on an average daily volume of 679,967 shares, the short-interest ratio is presently 0.9 days. Currently, 1.5% of the company’s shares are sold short. Currently, 1.5% of the company’s shares are sold short. Based on an average daily volume of 679,967 shares, the short-interest ratio is presently 0.9 days.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Benchmark reduced their price objective on shares of Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating on the stock in a research note on Wednesday, September 10th. Zacks Research raised Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a report on Monday. Finally, Wall Street Zen upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Harvard Bioscience has a consensus rating of “Hold” and a consensus target price of $2.00.

Harvard Bioscience Stock Up 1.7%

Shares of HBIO opened at $0.67 on Friday. Harvard Bioscience has a fifty-two week low of $0.28 and a fifty-two week high of $2.28. The company’s fifty day moving average is $0.66 and its two-hundred day moving average is $0.53. The firm has a market cap of $29.82 million, a PE ratio of -0.55 and a beta of 1.53.

Hedge Funds Weigh In On Harvard Bioscience

Large investors have recently modified their holdings of the company. Two Sigma Investments LP lifted its stake in shares of Harvard Bioscience by 139.7% in the 3rd quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock valued at $208,000 after purchasing an additional 276,372 shares in the last quarter. Williams & Novak LLC lifted its position in Harvard Bioscience by 158.5% during the third quarter. Williams & Novak LLC now owns 275,500 shares of the medical instruments supplier’s stock valued at $121,000 after buying an additional 168,930 shares in the last quarter. AMH Equity Ltd lifted its position in Harvard Bioscience by 15.4% during the third quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock valued at $1,775,000 after buying an additional 538,832 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Harvard Bioscience by 278.3% during the third quarter. Assenagon Asset Management S.A. now owns 139,220 shares of the medical instruments supplier’s stock worth $61,000 after buying an additional 102,419 shares during the period. Finally, Jane Street Group LLC increased its position in shares of Harvard Bioscience by 491.9% in the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 58,785 shares in the last quarter. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.